Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

NCT07889284 is registered in ClinicalTrials.gov with ScandiBio Therapeutics AB as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07889284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout
Lead sponsor
ScandiBio Therapeutics AB
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 28, 2027
Enrollment
336 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gout disease

Arms

As registered; 2 arms.

  • Treatment Arm ExperimentalCombined metabolic activators
  • Placebo Arm Placebo comparatorCollagen and maltodextrin

Primary endpoints

Registered primary outcome measures; 1 primary.

  • To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo. 4 weeks

    Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

Lead sponsor's other trials

ScandiBio Therapeutics AB, most recent start first.

Similar trials

Same condition (Hyperuricemia) and phase, most recent start first.